Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
BMJ Publishing Group
2021-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/9/11/e001806corr1.full |